STEM CELL LABORATORY (STCL)spitfire.emmes.com/study/duke/SOP/Flow Cytometry... · fr170-K^O-AVO^J...
8
InfoCard #: FLOW-GEN-044 Rev. 03 Effective Date: 05 Aug 2019 STEM CELL LABORATORY (STCL) DOCUMENT NUMBER: FLOW-GEN-044 DOCUMENT TITLE: Performance Verification of Un-assayed Antibodies DOCUMENT NOTES: Document Information Revision: 03 Vault: FLOW-General-rel Status: Release Document Type: FLOW SOPs Date Information Creation Date: 28 Jun 2019 Release Date: 05 Aug 2019 Effective Date: 05 Aug 2019 Expiration Date: Control Information Author: MGREESE Previous Number: FLOW-GEN-044 Rev 02 Owner: Change MGREESE Number: STCL-CCR-462 CONFIDENTIAL - Printed by: ACM93 on 05 Aug 2019 09:58:05 am
Transcript of STEM CELL LABORATORY (STCL)spitfire.emmes.com/study/duke/SOP/Flow Cytometry... · fr170-K^O-AVO^J...
InfoCard #: FLOW-GEN-044 Rev. 03 Effective Date: 05 Aug 2019
STEM CELLLABORATORY (STCL)
DOCUMENT NUMBER: FLOW-GEN-044
DOCUMENT TITLE:
Performance Verification of Un-assayed Antibodies
DOCUMENT NOTES:
Document Information
Revision: 03 Vault: FLOW-General-rel
Status: Release Document Type: FLOW SOPs
Date Information
Creation Date: 28 Jun 2019 Release Date: 05 Aug 2019
Effective Date: 05 Aug 2019 Expiration Date:
Control Information
Author: MGREESE
Previous Number: FLOW-GEN-044Rev 02
Owner:
Change
MGREESE
Number: STCL-CCR-462
CONFIDENTIAL - Printed by: ACM93 on 05 Aug 2019 09:58:05 am
InfoCard #: FLOW-GEN-044 Rev. 03 Effective Date: 05 Aug 2019
FLOW-GEN-044PERFORMANCE VERIFICATION OF UN-ASSAYED ANTIBODIES
1 PURPOSE
1. 1 The purpose of this procedure is to describe how antibodies that currently have nocommercially available pre-assayed positive control are tested to ensure properperformance in defined assays.
2 INTRODUCTION
2. 1 One aspect of quality control in flow cytometry assay is monitoring reagentperformance based on predetermined criteria. Many commonly used lymphocytesubset markers are easily monitored by the use of commercially availablestabilized process control cells with established range of expected values.However, when an antibody is less commonly used, it becomes more challengingto find an appropriate source for positive control material. One good sourcematerial is peripheral blood from normal heathy donors, particularly when usingantibodies to antigens that are found on the surface of lymphocytes, monocytes, orgranulocytes consistently.
3 SCOPE AND RESPONSIBILITIES
3. 1 This procedure is to be used to monitor proper performance of antibodies whichhave been optimized for use in a defined assay and for which there is nocommercially available process control with pre-assayed ranges. It is theresponsibility of the lab director, lab manager, flow cytometry supervisor, flowcytometry staff to ensure that this procedure is followed.
4 DEFINITIONS/ACRONYMS
4. 1 BDT-Becton Dickinson
4.2 SCE-Stem Cell Enumeration
4. 3 CD-Cluster Designation
4. 4 PBS-Phosphate buffered saline
4. 5 BSA-Bovine Serum Albumin
5 MATERIALS
5. 1 Antibody reagents to be tested
5.2 Peripheral blood collected in sodium heparin or EDTA anticoagulant vacutainer
5. 3 FACS Lysing Solution (at IX concentration with deionized and filtered water),BD Biosciences
5.4 PBS with 1% BSA (wash reagent), Gibco
FLOW-GEN-044 Perfonnance Verification ofUn-assayed AntibodiesStem Cell Laboratory, DUMCDurham, NC
CONFIDENTIAL - Printed by: ACM93 on 05 Aug 2019 09:58:05 am
Page 1 of 6
InfoCard #: FLOW-GEN-044 Rev. 03 Effective Date: 05 Aug 2019
EQUIPMENT
6. 1 Flow cytometer
6. 2 Vortex mixer
6. 3 Timer
6.4 12 x 75 mm BD FalconT polystyrene tubes (or equivalent)
6. 5 Calibrated 10, 200, 1000 |^1 micropipette, (Rainin or equivalent)
6.6 Micropipette tips for appropriate volumes.
6. 7 2 ml automated pipette and tips (Rainin or equivalent)
6. 8 Centrifuge, Beckman Coulter Alegra 6KR
SAFETY
7. 1 Review MSDS for reagents used in testing.
7. 2 Sodium azide warning
7. 3 BD FACS Lysing solution
7. 4 Use universal precautions and wear appropriate personal protective equipment(PPE) when working with biohazardous materials.
PROCEDURE
8. 1 Identify antibody or antibody cocktail to be tested.
8. 2 Once per month or as needed obtain peripheral blood test samples from normalhealthy donor.
8. 3 Follow the assay procedure for staining, acquisition, and analysis as you would apatient test sample.
8.4 Use the file name NORMAL mmddyy.
NOTE: In order to assess antibodies that are used to set fluorescent threshold inthe lyse/no wash method, it is necessary to wash the excess reagent from the tubein order to use a forward scatter threshold and gate on the appropriate populationvia light scatter properties free of excess antibody and debris.
8. 5 Add 1 ml ofPBS wash reagent to the appropriate tubes (i.e. tubes 3,5, 6,7 ofimmune recon panel) and to the compensation optimization tubes used tooptimize the LNW settings.
8. 6 Centrifuge these tubes at 300g (-1200 rpm) for 5 minutes.
8.7 Remove tubes and decant the supernatant.
8. 8 Re-suspend the pellet in 300 ̂ il ofPBS wash reagent.
8. 9 It will be necessary to perform the compensation optimization using the Calib File(Lyse/Wash) settings prior to re-acquiring test tubes that are washed.
8. 10 Optimize the FSC threshold level to eliminate excess debris (usually around 100-150).
FLOW-GEN-044 Perfonnance Verification ofUn-assayed AntibodiesStem Cell Laboratory, DUMCDurham, NC
CONFIDENTIAL - Printed by: ACM93 on 05 Aug 2019 09:58:05 am
Page 2 of 6
InfoCard #: FLOW-GEN-044 Rev. 03 Effective Date: 05 Aug 2019
8. 11 Save these settings as Calib file opt. and leave them in place for acquiring washedsamples.
8. 12 Continue acquisition run order using the same data file name and starting withnext file increment number.
8. 13 Align the cursor in the parameter description window to correspond with the tubethat is being re-acquired.
8. 14 The table below includes the analysis templates currently used for this qualitycontrol testing.
Analysis templatesTemplate
Clinical IR QC T-3&6 CDS
Clinical IR QC T-3 CD45RA-CD62L
IRQC T4 CD25andCD62L
IR QC T-5 CD57 CD28
IR QC T-5 CD8 &HLA-DR APC
IR QC T-7 UN & HLA-DR PCP
* MT = multitest
**RTE = Recent Thymic Event
File Increment
9 (washed 3)11 (washed 6)
3 and 6 (iso)
4 and 6 (iso)
5 and 6 (iso)
10 (washed 5)
12 (washed 7)
Results
CD3% MT* as % LymphsCD3%PCP as % Lymphs
CD62L% MT as CDSCD45RA% MT as CDSRTE**
'^J'TCT'r I I C~!TS~ yo'
[^A&^CD4% ARC as %CD3
^ CD57% FlTCTai~%E'D8l|bright
.CD2&% EITC. a.<,J/nCl
CD8%PCPcy5. 5as%Lypmhs
TlT'^DR'^APC Js Wmonocytes
yUN-l%FITC'as3T^
HLA-DR% PCP as %monocytes
FLOW-GEN-044 Performance Verification ofUn-assayed AntibodiesStem Cell Laboratory, DUMCDurham, NC
CONFIDENTIAL - Printed by: ACM93 on 05 Aug 2019 09:58:05 am
Page 3 of 6
InfoCard #: FLOW-GEN-044 Rev. 03 Effective Date: 05 Aug 2019
8. 15 Analysis examples for Immune Reconstitution panel:
Clinical IR QC T-3&6 CDS (wash) Clinical IR QC T-3 CD45RA-CD62L
TiAe 3 ani Tube 6 03 QC
UT CD} AS* LYMPHS. 71.01
C03PCfTl8E6. 69. 17
- a .»%«»
TU8E3
.<<».~;7»g»
GS. «la«l«SG9. «I nd «S ami RE
Ifl tt» N»f
WMWMfs^SO
^^
*_«.^
C041MASKOFC03" }0. 9S
C(»2l*&SOItCUl»73.M
C04AS?fc01tCOi-6), 4S
TUB6KO
'«si»uu»iiitai*
fB "< li''.. '".;
CS-111 »ndBS(»-lt1»ndlli«n(t»6
Clinical IR QC T4 CD25 and CD62L Clinical IR QC T5 CD57 CD28
IIw»»*te»t6iknx
LA
MJIWUMWtlM
^tt
> »'
.»
X.«' » igf
tltN>MtA*4TiOO*
t^ .. »^>twwcnrtn*-tdbt*
t<*wt0*ai!tt»
r*x»wON* D*Ort*Bt.*nfwt*
Bu**(
SUB E<
*ifl>n*<tt«
K >«n
rt!0*n.KM»raurftc^tiwn
MINtt <»^'
WKWWUUBTtiBMo»* a*G*N«E,WW »<»X^WntMfWy
C6<«fCfl
>i^i_c«m» %a<i»*l* tU
U> »t* *N
Plft)
'8iw T »C040fC03. tl. li
Gi. Bl»«»5G9- 111 and RS and RS
Bndlt nptxd M <CO< nh
MD2S Of C04 POS. 17.02
«CD62LOFCWroS.7Ui
^
Ihtfj
;v
f'T
wffi
si'-'y
.. tSi
^R:3?
iCNtttiUli»ttt»
<ffl
v^»^»<SmvtwCWTOt:fl»»
flWttK»N If *)
UN » BU B«?
BwutK txpw. Md . w <t C&t M%
»OK70FCDIb. i<klS. ;l
*CD;tofCOBtol9l«S2.I;
CS-BlandftSfi6- M »d a^
FLOW-GEN-044 Performance Verification ofUn-assayed AntibodiesStem Cell Laboratory, DUMCDurham, NC
CONFIDENTIAL - Printed by: ACM93 on 05 Aug 2019 09:58:05 am
Page 4 of 6
9jo$33t'd
uie 30:83:60 61.0Z Bny SO uo £61ftl3V :Aq psiuud - ~IVllN3airlN03
3is[ 'lueqjna
DWna '-OoiBjoqBq [[33 uisis
ssipoqpuv ps^ssB-UQjo uoiiBoyusA souBuuojjsd 17t70-N3r>-MO^J
^99qS l(ns3-a [O^uoo K}i{Bn^ lusg^s^ ̂3\uo^ MO(J '800-IA^aOJ-AVO^J I "6
swyo^/siNaiA[A3oa a^lv^au 6
.
SJB9^
^ ISB9[ IB JOJ 9[qE(IBAB s^nssj sql d93?( pue 9[y usqi 'SJQJJS uoiiduosueji psisp
oi jsquisiu jj^is p9iji|Bnb e Xq MSIASJ puooss B 9A1933J s^nssj sssqi iBqi gjnsug ^fg
.
Ajiaiuo^X^ MO[J JQJS9pi[0j (OJIU03 Xii(Bn^)-iu9iu9§BUEp\[ ^li^n^ Xjo^oq^^ ((93 lugig 'OZO-N30
-^Oqj u; p9ui[ino si[ns9j 9[qBid930Bun §u;iooL[S9[qnoji joj S9[nj sql AVOI[OJ g ["g
.
\W&d fr170-K^O-AVO^J 01 ss^BpdnSB [OJIU03 9§u^q3 BIA uisisXs (OJiuoysiSB^ sq-t ui psiusuinoop pUB sjnpsoojd siqiui psquossp SB psuijojjsd sq |(IM ssgum 9(qBid933Bjo SUOISIASJ sjninj .psiumjBM.
9JB SlUSLU^SnfpEJI 9UlUU9l9p 01 X[(E3IpOU9d p9M31A9J 9q [[IM 3§UBJ SVft '9UIII
J9AO (ood jouop gui§UBqo sql pue uisisKs suniuiui sql jo sjn^u 9(qBui3A sql 01 snQ.
UB9UI sql uiojj suoi^iAsp pjBpu^s ^+ §upB[no[B3 Xq psuiiiuspp usqi s; JS-^JBLU
q3B9 joj 3§um sql puo IS9J91UIJO J9^JBIU q3E9 JOJ 9n|BA UB9UI sql qsiiq^ss o'> pssn9JB SJOUOp Xqi|B9q SJOUl JO $ LUOJJ ssnpA oz UBI[I J9M9J 0{\[ .S[SX[Bire |BOtlSI1BlSJO
ssodjnd sql JQJ ̂sqspBSjds ""[33X3 UB olul p9.i3iu9 SJB Suiissijo s^nssj sqj^ .SLUBJJ
9LU11 JB9X OAY} B ISB91 }V J9AO XjqiUOLU SJ99lun[OA XqiIBSq UO p3LUJOJ.I9d §UllS9l UIOJJ
UOpBIASp pJBpUElS pUB UB9LU Sql §UlUIBiqO Xq p9qSI(qBlS9 3JB S9§UPJ 9(qBld930^ 9qj^ ,,{.8
.
93ircUUOJJ9d XjU9A 01 9§UBJ90UBld933B p9UIJ9p 3qi 0} §UpS9lJO si[ns9J: sql sjBdiuoo pue 'issqg l{nS9'y [OJIUOO
^KIBn^) iu9§B9-y ^190101X3 MO[J '
[ y^d t7170-NaO-MO^J "o si[ns9.i 941 pjoos^ 9 [ .8
tfti'MKmxim-nm
as
»flWilluiWNO-
.
t>»*«>*3
»
lift^s.
<>i ww
*3CT»*tftirtu"
in11wn
3 WffO
IWKI.IA»3i»ntO<TO
tkotitXCmnuON *>i
LOO100*t«*It»
t
t
it»^C»t<Z
tfln
-s-
-Sfti
iinitwwnw
11 96 -SONOW 10 Wt Dfl-VTH*
wo < inBOO 0 n*» H vtu unwe i* inp^g-k *»»3 pmo
Q*t t« MWVtffWSro*ro
SMVWKWtWH If
^ ^^" f
-"SNfr
wvwvwnuw
S9E6a38M,tONnK PWO^ *w3 woszK-SHdNAiioaax
otodtiwwnuoNW
SifWWTWWW
»^u? ^-g5
!sa
iiflStfiiwMiacw
(qs^M) (qsBM)
^a-v^H v "n LL 3^) 'ai poiuio Ja-v^H ̂ 800 Sl 3^) ̂II IB:)!U!13
61.03 Bny SO :s»ea SAIPSJJ^ £0 'Asy fTO-NBS-MO-IJ :# PJEQOIUI
InfoCard #: FLOW-GEN-044 Rev. 03 Effective Date: 05 Aug 2019
9. 2 FLOW-GEN-020, Stem Cell Laboratory Quality Management-Quality ControlPolicies for Flow Cytometry
9. 3 FLOW-GEN-044 FRM1, UN-ASSAYED ANTIBODIES RECORD SHEET
10 REFERENCES
10. 1 Clinical Laboratory Improvements Amendments of 1988 (102 Stat. 2903, PublicLaw 100-578)
11 REVISION HISTORY
Revision No.
03
Author
M. Reese
Description of Change(s)Added explanation for acceptable range determination.Explained how/why acceptable ranges will be reviewed.Added FRM 1 to the related documents.
FLOW-GEN-044 Performance Verification ofUn-assayed AntibodiesStem Cell Laboratory, DUMCDurham, NC
CONFIDENTIAL - Printed by: ACM93 on 05 Aug 2019 09:58:05 am
Page 6 of 6
InfoCard #: FLOW-GEN-044 Rev. 03 Effective Date: 05 Aug 2019
Signature Manifest
Document Number: FLOW-GEN-044
Title: Performance Verification of Un-assayed Antibodies
Revision: 03
All dates and times are in Eastern Time.
FLOW-GEN-044 Performance Verification of Un-assayed Antibodies
Author
Name/Signature | Title
Melissa Reese (MGREESE)
Management
j Date10 Jul 2019, 10:41:55 AM
} Meaning/ReasonApproved
j Nlame/&gnatureBarbara Waters-Pick
(WATE02)
IWedical Director
Title Date
10 Jul 2019, 01:15:40 PM
j Meaning/Reason
Approved
] Name/Signature
Joanne Kurtzberg(KURTZ001)
Quality
Title I. i?a^. - ._ . 1 ..!^e?rll??^eason
10 Jul 2019, 06:27:02 PM Approved
LJy?.1l?J^.lSL[15lyL^__J-l!.tJS.(RB232 ) for Bing Shen (BS76)Isabel Storch(IMS19)
Lisa Eddinger (LE42)Taylor Orr (TS04)
Richard Bryant (RB232)
Document Release
Date Meaning/Reason
11 Jul 2019, 01:52:59 PM Approved
Name/Signature
Sandy Mulligan (MULL1026)_|jjtle
.
J.,.Diltl25 Jul 2019, 05:33:49 PM
season
Approved
CONFIDENTIAL - Printed by: ACM93 on 05 Aug 2019 09:58:05 am
